AZD 1775
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Conditions
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Trial Timeline
Jul 1, 2015 → Aug 22, 2019
NCT ID
NCT02482311About AZD 1775
AZD 1775 is a phase 1 stage product being developed by AstraZeneca for Ovarian Cancer, TNBC, SCLC, Other Solid Tumours. The current trial status is completed. This product is registered under clinical trial identifier NCT02482311. Target conditions include Ovarian Cancer, TNBC, SCLC, Other Solid Tumours.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02482311 | Phase 1 | Completed |
Competing Products
20 competing products in Ovarian Cancer, TNBC, SCLC, Other Solid Tumours